Consolidated balance sheet as at December 31
(in CHF 1 000)
|
|
|
Notes |
|
2020 |
|
2019 |
|
Current assets |
|
|
|
|
|
|
|
Cash and cash equivalents |
|
|
|
6 816 |
|
30 707 |
|
Receivables from brokers |
|
|
|
1 521 |
|
– |
|
Securities |
|
4 |
|
3 954 659 |
|
3 523 670 |
|
Other assets |
|
|
|
139 |
|
190 |
|
|
|
|
|
3 963 135 |
|
3 554 567 |
|
Total assets |
|
|
|
3 963 135 |
|
3 554 567 |
|
|
|
|
|
|
|
|
|
Current liabilities |
|
|
|
|
|
|
|
Short-term borrowings from banks |
|
5 |
|
63 000 |
|
150 000 |
|
Payables to brokers |
|
|
|
6 576 |
|
6 359 |
|
Other short-term liabilities |
|
6 |
|
5 709 |
|
4 992 |
|
Tax liabilities |
|
|
|
303 |
|
243 |
|
|
|
|
|
75 588 |
|
161 594 |
|
Total liabilities |
|
|
|
75 588 |
|
161 594 |
|
|
|
|
|
|
|
|
|
Shareholders' equity |
|
|
|
|
|
|
|
Share capital |
|
7 |
|
11 080 |
|
11 080 |
|
Treasury shares |
|
7 |
|
(8 241) |
|
– |
|
Retained earnings |
|
7 |
|
3 884 708 |
|
3 381 893 |
|
|
|
|
|
3 887 547 |
|
3 392 973 |
|
Total liabilities and shareholders' equity |
|
|
|
3 963 135 |
|
3 554 567 |
|
|
|
|
|
|
|
|
|
Net asset value per share in CHF |
|
|
|
70.30 |
|
61.25 |
The notes are an integral part of the consolidated financial statements.
The consolidated financial statements were approved by the Board of Directors of BB Biotech AG on February 16, 2021.